CONMED CORPORATION Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
CONMED CORPORATION (CNMD) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$943.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-29
- CONMED CORPORATION effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $819.00K.
- CONMED CORPORATION effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$513.00K, a 269.31% decline year-over-year.
- CONMED CORPORATION effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $303.00K.
- CONMED CORPORATION effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2022-03-31 was -$113.00K.
- CONMED CORPORATION effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $2.44M.
- CONMED CORPORATION effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$2.72M, a 678.94% decline from fiscal 2023.
- CONMED CORPORATION effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $470.00K.
- CONMED CORPORATION effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$741.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$943.00K 10-Q · filed 2026-07-29 | |||
| 2025-12-31 | $2.44M 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $2.41M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $2.39M 10-Q · filed 2026-07-29 | |||
| 2025-03-31 | $819.00K 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | -$2.72M 10-K · filed 2026-02-17 | |||
| 2024-09-30 | -$485.00K 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$1.13M 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | -$513.00K 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $470.00K 10-K · filed 2026-02-17 | |||
| 2023-09-30 | -$550.00K 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | $300.00K 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $303.00K 10-Q · filed 2024-04-25 | |||
| 2022-12-31 | -$741.00K 10-K · filed 2025-02-18 | |||
| 2022-09-30 | -$2.73M 10-Q · filed 2023-10-26 | |||
| 2022-06-30 | -$1.42M 10-Q · filed 2023-07-27 | |||
| 2022-03-31 | -$113.00K 10-Q · filed 2023-04-27 | |||
| 2021-12-31 | -$1.86M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | -$1.39M 10-Q · filed 2022-10-27 | |||
| 2021-06-30 | -$521.00K 10-Q · filed 2022-07-28 | |||
| 2021-03-31 | -$950.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $2.67M 10-K · filed 2023-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |